BioCardia, Inc. (BCDA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

BioCardia released Q1 2026 financial results on May 15, 2026, providing transparency on operational performance for the quarter ended March 31, 2026.
The company is traded on Nasdaq Capital Market under ticker BCDA with registered warrants (BCDAW), indicating a small-cap biomedical device company structure.
This is a routine quarterly earnings announcement with no material events, acquisitions, leadership changes, or significant business developments disclosed in the 8-K filing itself.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-08

FDA confirmed two viable regulatory pathways for Helix Transendocardial Delivery Catheter System approval, with no safety or performance concerns raised, reducing development risk for the company's key device.
FDA's preferred approval route is simultaneous clearance of Helix with CardiAMP cell therapy for heart failure treatment, suggesting regulatory alignment and potential for combined market entry that could accelerate commercialization.
Alternative DeNovo pathway approval option provides strategic flexibility if the simultaneous approval strategy faces delays, giving BioCardia multiple routes to market for its lead product.

Filed: 2026-04-28

BioCardia received allowance of a Japanese patent for Heart3D™ Fusion Imaging technology, strengthening intellectual property protection for their proprietary image-guided navigation software used in CardiAMP Cell Therapy procedures.
The patent covers 'Target Site Selection, Entry, and Update with Automatic Remote Image Annotation,' indicating innovation in real-time surgical guidance capabilities that could enhance competitive positioning in interventional cardiology.
This international patent protection expansion suggests BioCardia is pursuing global market opportunities and building a defensible moat around their core Heart3D technology platform.

Filed: 2026-04-15

BioCardia, Inc. has failed to meet the minimum stockholders' equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market, and the company has until May 25, 2026 to submit a plan to regain compliance.
The company's inability to meet the listing requirement may indicate financial difficulties or challenges in the business that could impact its long-term viability.
Investors should closely monitor the company's progress in submitting a plan and regaining compliance, as a potential delisting from Nasdaq could significantly affect the stock's trading and liquidity.

Filed: 2026-04-02

BioCardia has submitted the CardiAMP HF clinical study data to the FDA, indicating potential progress in the development of their lead product candidate.
The company plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP System for ischemic chronic heart failure with reduced ejection fraction (HFrEF), which could expedite the approval process.
The company's ability to navigate the regulatory landscape and potentially obtain accelerated approval for the CardiAMP System could be a significant milestone for the company and its investors.

Filed: 2026-03-24

BioCardia, Inc. announced its financial results for the year ended December 31, 2025, providing investors with an update on the company's performance and operations.
The 8-K filing does not indicate any material agreements, leadership changes, or other significant corporate events beyond the financial results disclosure.
Without additional context on the company's financials, product pipeline, or strategic initiatives, the significance of this filing is limited.

Filed: 2026-03-17

BioCardia, Inc. has received FDA acceptance of its pre-submission package for the Helix Transendocardial Delivery Catheter, indicating progress in the regulatory approval process for this key product.
The Helix catheter is intended for intramyocardial therapeutic and diagnostic agent delivery, which could expand BioCardia's product portfolio and addressable market.
Receiving FDA acceptance of the pre-submission package is an important milestone that suggests BioCardia is advancing its regulatory strategy for the Helix catheter.

Filed: 2026-03-03

BioCardia reported positive late-breaking echocardiography results from its Phase III clinical trial for ischemic heart failure, suggesting potential efficacy of their therapy.
The results were presented by a respected professor and co-principal investigator of the trial, lending credibility to the findings.
The favorable data, if confirmed, could significantly advance BioCardia's pipeline and increase investor confidence in the company's prospects.

Filed: 2026-02-10

BioCardia has completed a Pre-Submission under the Q-Submission program with the FDA for its Helix Transendocardial Delivery Catheter, a key step towards regulatory approval.
Successful completion of the Pre-Submission process could indicate progress in BioCardia's efforts to commercialize its catheter technology for intramyocardial therapeutic and diagnostic agent delivery.
Investors may want to monitor further updates on the FDA review process and the potential timeline for the Helix Catheter's approval and commercialization.

Other reports for BioCardia, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.